AIPSS‐MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib

BACKGROUND: In myelofibrosis (MF), new model scores are continuously proposed to improve the ability to better identify patients with the worst outcomes. In this context, the Artificial Intelligence Prognostic Scoring System for Myelofibrosis (AIPSS‐MF), and the Response to Ruxolitinib after 6 month...

Descripción completa

Detalles Bibliográficos
Autores principales: Duminuco, Andrea, Mosquera‐Orgueira, Adrian, Nardo, Antonella, Di Raimondo, Francesco, Palumbo, Giuseppe Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598243/
https://www.ncbi.nlm.nih.gov/pubmed/37553891
http://dx.doi.org/10.1002/cnr2.1881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598243/
https://www.ncbi.nlm.nih.gov/pubmed/37553891
http://dx.doi.org/10.1002/cnr2.1881

Ejemplares similares